Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-ACT319
- Development stage
- Phase 2
- Lead developer
- Actithera
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
177Lu-ACT319 is an investigational radiopharmaceutical (radioligand therapy) being developed by Actithera, Inc. It consists of the beta-emitting radioisotope lutetium-177 (177Lu) conjugated to ACT319, a targeting moiety designed to bind to fibroblast activation protein (FAP). FAP is highly expressed on cancer-associated fibroblasts within the tumor microenvironment of various solid tumors. By targeting FAP, 177Lu-ACT319 delivers localized beta radiation directly to the tumor site, sparing healthy tissues. The drug is administered intravenously and is currently being evaluated in a Phase 1/2 clinical trial for patients with FAP-expressing advanced solid tumors, with a primary focus on pancreatic ductal adenocarcinoma (PDAC) and biliary tract carcinoma.
- Other names
- 177Lu-labeled ACT319[177Lu]Lu-ACT319lutetium (177Lu) ACT319lutetium Lu 177 ACT319lutetium-177 ACT319lutetium177 ACT319lutetium 177 ACT319
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 177Lu-ACT319.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-ACT319.